Cronos Group Inc vs Banco Santander SA — how do they compare? Cronos Group Inc trades at $2.78 (market cap $1.02B), while Banco Santander SA trades at $13.71 (market cap $195.40B). The key difference: Banco Santander SA is far larger — about 191.6× Cronos Group Inc's market cap, and Banco Santander SA pays a 2.04% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | SAN | |
|---|---|---|
Market Cap | $1.02B | $195.40B |
Sector | Health | Financials |
52-Week High | $3.27 | $14.37 |
52-Week Low | $1.95 | $8.31 |
Enterprise Value | $203.29M | — |
Dividend Yield | — | 2.04% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Banco Santander (SAN) trades at $13.66, down 1.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.4144, beating expectations, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value. The stock shows a P/E of 13.57 and P/B of 1.62, indicating reasonable valuation relative to peers.
The outlook for SAN is positive, supported by record profitability, strategic acquisitions, and cost-saving measures. However, risks include declining cash flows, regulatory scrutiny in Spain, and macroeconomic pressures on loan growth. Analyst consensus is bullish with 64% buy ratings, but investors should monitor execution on efficiency targets and integration of recent acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →